Table 1.
Patient characteristics by clopidogrel response.
| Characteristics | All Patients (n = 515) | Responders (n = 268) | Non-Responders (n = 247) | P-Valuea |
|---|---|---|---|---|
| Adenosine diphosphate group | <.001 | |||
| ≤40% | 268 (52.0%) | 268 (100%) | 0 (0.0%) | |
| 40%−50% | 68 (13.2%) | 0 (0.0%) | 68 (27.5%) | |
| >50% | 179 (34.8%) | 0 (0.0%) | 179 (72.5%) | |
| Arachidonic acid (%) | 15.0 (9.0–27.0) | 11.0 (7.0–17.0) | 21.0 (13.0–30.0) | <.001 |
| Arachidonic acid ≤20% | 337 (65.4%) | 216 (80.6%) | 121 (49.0%) | <.001 |
| Time from clopidogrel load to lab measurement (hours) | 32.0 (20.7–64.6) | 32.0 (21.1–66.3) | 29.7 (20.4–63.0) | .64 |
| Time from clopidogrel load to lab measurement by group | .64 | |||
| <24 hours | 183 (38.0%) | 92 (36.1%) | 91 (40.1%) | |
| 24–48 hours | 161 (33.4%) | 74 (29.0%) | 64 (28.2%) | |
| >48 hours | 138 (28.6%) | 89 (34.9%) | 72 (31.7%) | |
| Clopidogrel load strength | .23 | |||
| 300 mg | 172 (33.5%) | 93 (34.8%) | 79 (32.0%) | |
| 600 mg | 310 (60.3%) | 162 (60.7%) | 148 (59.9%) | |
| No load | 32 (6.2%) | 12 (4.5%) | 20 (8.1%) | |
| Targeted temperature management when loaded | 9 (1.8%) | 2 (0.7%) | 7 (2.8%) | — |
| Clopidogrel manufacturer | .01 | |||
| Manufacturer 1 | — | 23 (8.6%) | 43 (17.4%) | |
| Manufacturer 2 | — | 38 (14.2%) | 31 (12.6%) | |
| Unknown manufacturer | — | 206 (77.2%) | 173 (70.0%) |
Data presented as mean ± standard deviation, median (interquartile range), or number (%).
a
P-values for comparison between responders and non-responders.